Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Table 1 Patient characteristics and response summary

Patient no.	Age	Sex	Cytogenetics at diagnosis	Previous treatment	Number of relapses	Marrow blasts (% of mononuclear)		CAR dose (10⁶/kg)	Response (day 30)	Months until relapse after CAR	CRS	Neurological toxicity
Patient no.	Age	Sex	Cytogenetics at diagnosis	Previous treatment	Number of relapses	Pre-treatment (%)	Post-CAR (%)	CAR dose (10⁶/kg)	Response (day 30)	Months until relapse after CAR	CRS	Neurological toxicity
1	23	M	Normal karyotype	C	2	39.94	< 0.01	3	CR, MRD Neg	10	Grade 1	None
2	24	F	Normal karyotype	C	2	55.27	< 0.01	2	CR, MRD Neg	5	Grade 1	None
3	44	F	Normal karyotype	C	3	5.81	< 0.01	2	CR, MRD Neg	11+	Grade 1	None
4	17	M	Normal karyotype	C	1	54	< 0.01	3	CR, MRD Neg	3	Grade 1	None
5	20	M	Complex including 12p13 deletion	C, R	2	3.66	< 0.01	2	CR, MRD Neg	8+	Grade 2	None
6^#	39	M	Ph⁺	C	2	89.14	< 0.01	1.7	CR,MRD Neg	8+	Grade 2	None

M male, F female, C chemotherapy, R radiation therapy, CR complete remission, CRS cytokine release syndrome, MRD minimal residual disease
^#Patient 6 received allo-hematopoietic stem cell transplant 2 months after CD19/CD22 CAR T cell therapy

ISSN: 1756-8722